- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Katerzia, Norliqva, Norvasc
Synonyms :
Class :
Antianginal agents; Calcium channel blockers
Dosage forms & Strengths:
Adult:
Tablet:
2.5 mg
5 mg
10 mg
Oral suspension/solution:
1 mg/ml
Initiate treatment with an oral dose of 5 mg per day
The dosage can be raised by 2.5 mg per day every 7 to 14 days if necessary
However, the maximum recommended daily dose should not exceed 10 mg
For maintenance, a daily dosage range of 5 to 10 mg is typically advised
Initiate treatment with an oral dose of 5-10 mg per day
Afterward, the maintenance dosage should be adjusted to 10 mg per day orally
Age: 6-17 years
The use of doses exceeding 5 mg/day orally has not been investigated
The recommended dosage range is 2.5 to 5 mg per day
may enhance the concentration of serum when combined with simvastatin
may enhance the serum concentration of amlodipine
it may enhance the effects when combined with lofexidine by pharmacodynamic synergism
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of amlodipine
when both drugs are combined, there may be an increased risk of adverse effects
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
The serum concentration of amlodipine can be increased by strong inhibitors of CYP3A4
The serum concentration of amlodipine can be increased by strong inhibitors of CYP3A4
The serum concentration of amlodipine can be increased by strong inhibitors of CYP3A4
The serum concentration of amlodipine can be increased by strong inhibitors of CYP3A4
The serum concentration of amlodipine can be increased by strong inhibitors of CYP3A4
amlodipine: they may diminish the serum concentration of CYP3A4 Inducers
amlodipine: they may diminish the serum concentration of CYP3A4 Inducers
It may diminish the effect when combined with griseofulvin by CYP3A4 metabolism
it may diminish the therapeutic efficacy when combined with castor oil
When levobupivacaine and amlodipine are combined, the risk or seriousness of adverse events will rise
amlodipine: they may enhance the serum concentration of CYP3A Inhibitors
amlodipine: they may enhance the serum concentration of CYP3A Inhibitors
amlodipine: they may enhance the serum concentration of CYP3A Inhibitors
amlodipine: they may enhance the serum concentration of CYP3A Inhibitors
amlodipine: they may enhance the serum concentration of CYP3A Inhibitors
the effect of amlodipine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
fedratinib increases the effect of amlodipine by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
CYP3A4 inhibitors increase the concentration of amlodipine in serum
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may decrease the serum concentration of activated charcoal
>10%:
Edema
1-10%:
Headache
Fatigue
Palpitations
Dizziness
Nausea
Flushing
Abdominal pain
Somnolence
Asthenia
Pruritus
Skin rash
Muscle cramps
Male sexual dysfunction
<1%:
Anemia
Depression
Somnolence
Migraine
Vertigo
Dyspnea
Nausea
Abdominal pain
Impotence
Edema
Urticaria
Myalgia
Tinnitus
Amlodipine is contraindicated in patients hypersensitive to the formulation’s active ingredient and other excipients.
Pregnancy consideration:
No complete information available for usage in pregnant women
Breastfeeding warnings:
The drug excretion in breastmilk is unknown
Pregnancy category:
Patient information leaflet
Generic Name: amlodipine
Pronounced: am-loh-dip-ine
Why do we use amlodipine?
Amlodipine treats hypertension, coronary artery disease, and angina pectoris.